American Cyanamid Company

Micrologix Biotech Inc.

Biosource Pharm, Inc.

Migenix, Inc.

Biowest Therapeutics Inc.

Donald B Borders

Raymond T Testa

David P Labeda

Amedeo A Fantini

Joseph J Goodman

William V Curran

May D Lee

William M Maiese

Jane P Kirby

Richard A Leese

Guy T Carter

John H Martin

Howard Jarolmen

Michael Greenstein

John H Martin, Deceased

Noreen D Francis

Taikwang M Lee

Raymond C Yao

Noreen Francis

Dale R Cameron

Qi Jia

William J McGahren

Matthew B Nodwell

Yuchen Chen

Homer D Tresner

Vincent A Boyd

Douglas W Phillipson

Joseph D Korshalla

Paulo W M Sgarbi

Shirley A Wacowich-Sgarbi

Dominique Dugourd

Disclosed herein are novel peptides and protected peptides. These compounds can be derived from naturally occurring peptides, such as those selected from colistin, circulin A, polymyxin A, polymyxin B, polymyxin D, octapeptin B, octapeptin C, and [Ile]polymyxin B. Also disclosed are pharmaceutical compositions containing the new peptides, as well as methods for preparing the novel peptides and protected peptides.

Peptide antibiotics and methods for making same

The present invention provides derivatives of lipopeptide antibiotics that display antimicrobial activity against microorganisms, methods and compounds for synthesizing such antimicrobial derivatives and analogues, and methods of using the compounds in a variety of contexts, including in the treatment and prevention of microbial infections.

Compositions of lipopeptide antibiotic derivatives and methods of use thereof

The present invention provides a rapid and inexpensive method for extractively isolating acidic lipopeptide antibiotics, such as those having a cyclic peptide or cyclic depsipeptide core, in high yield and purity. In particular, there is provided a method of extracting a variety of acidic lipopeptide antibiotics, directly or indirectly, into water immiscible organic solvents by using a divalent cation chelation procedure.

Extractive purification of lipopeptide antibiotics

Novel cyclodepsipeptide intermediates have been prepared from the A21978 complex and used to synthesize new lipodepsipeptide antibiotics. The three intermediates can be readily derivatized to give new families of antibiotics that have potent antibacterial activity against gram positive bacteria.

Lipodepsipeptide antibiotics and methods of preparation

The present invention provides antimicrobial sulfonamide derivatives of lipopeptide antibiotics, pharmaceutical compositions of antimicrobial sulfonamide derivatives, methods for making antimicrobial sulfonamide derivatives, methods for inhibiting microbial growth with antimicrobial sulfonamide derivatives and methods for treating or preventing microbial infections in a subject with antimicrobial sulfonamide derivatives. Antimicrobial sulfonamide derivatives are generally an amino core antibiotic that has been further modified with a lipophilic sulfonyl group.

Antimicrobial sulfonamide derivatives of lipopeptide antibiotics

The present invention provides laspartomycin core peptides, laspartomycin core peptide derivatives, antimicrobial laspartomycin derivatives, methods for making laspartomycin core peptides, methods for making laspartomycin core peptide derivatives, methods for making antimicrobial laspartomycin derivatives, pharmaceutical compositions of antimicrobial laspartomycin derivatives, methods of inhibiting microbial growth and methods for treating and/or preventing microbial infections in a subject.

Derivatives of laspartomycin and preparation and use thereof

This method is for preparing salts of amphotericin B methyl ester and other polyene macrolide esters. The steps of the process involve methylation by use of cesium carbonate for converting to methyl ester and significantly reducing side products, which are over methylation products. The free base-Schiff base mixture is converted to amphotericin B methyl ester hydrochloride or some other salt form, by using tetrahydrofuran-water to dissolve the mixture for acid treatment to obtain the salt. The aldehyde liberated during salt formation is removed by centrifuging, as to any precipitated aldehyde, and the aldehyde remaining in solution is removed by eluting the solution through a reverse phase adsorbent to obtain amphotericin B methyl ester hydrochloride as a yellow powder.

Method for preparing salts of polyene macrolide esters

The present invention provides a laspartomycin core peptide, a laspartomycin core peptide derivative, a antimicrobial laspartomycin derivative, a method for making laspartomycin core peptides, methods for making laspartomycin core peptide derivatives, methods for making antimicrobial laspartomycin derivatives, pharmaceutical compositions of antimicrobial laspartomycin derivatives, methods of inhibiting microbial growth and methods for treating and/or preventing microbial infections in a subject.

Derivatives of antibiotics derived from the microorganism Streptomyces lydicus subspecies tanzanius, referred to as antibiotics LL-E19020 alpha and beta, are produced by chemical reaction. The derivatives are also active antibiotics useful in the treatment of bacterial infections.

Chemical derivatives of antibiotics LL-E19020 alpha and beta

This invention provides a method for treating chronic respiratory disease, fowl cholera and necrotic enteritis in infected birds, by orally administering thereto a pharmaceutically effective amount of antibiotic LL-E19020.alpha., antibiotic LL-E19020.beta. or a physiologically acceptable salt thereof.

Method for controlling chronic respiratory disease, fowl cholera and

A new antibacterial agent designated LL-C19004 is described, which antibacterial agent is produced through microbiological fermentation, under controlled conditions using a new species of Saccharothrix, Saccharothrix espanaensis (NRRL 15764).

Antibiotic LL-C19004

Antibiotic LL-D42067.beta. derived by aerobic fermentation of the microorganism Actinomadura madurae subspecies simaoensis NRRL 15734, useful as an antibacterial and antiparasitic agent.

Antibiotic LL-D42067.beta.

A biologically pure culture of Micromonospora purpureochromogenes ssp. Wuxiensis and its use in an aerobic fermentation process to produce the antibacterial and antiparasitic agent LL-D42067.alpha..

Process for producing antibiotic LL-D42067.alpha.

The invention is a process for the production by fermentation of the antibacterial and antiparasitic agents designated LL-D42067.alpha., to methods for its recovery and concentration from crude solutions and to processes for its purification. The invention includes within its scope the biologically pure culture of the antibiotic.

Growing community of inventors

Suffern, NY, United States of America

Donald B Borders